Progenics Plummets on Rejection of New Use of Relistor

Progenics Pharmaceuticals Inc. fell the most in four years after failing to gain U.S. approval to expand use of its constipation medicine Relistor licensed to Salix Pharmaceuticals Ltd.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.